Abstract
RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Volume: 9 Issue: 3
Author(s): Gabriel Courties, Jessy Presumey, Isabelle Duroux-Richard, Christian Jorgensen and Florence Apparailly
Affiliation:
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Abstract: RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Export Options
About this article
Cite this article as:
Courties Gabriel, Presumey Jessy, Duroux-Richard Isabelle, Jorgensen Christian and Apparailly Florence, Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (3) . https://dx.doi.org/10.2174/1871523011009030251
DOI https://dx.doi.org/10.2174/1871523011009030251 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity
Current Medicinal Chemistry Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Case Report
Current Clinical Pharmacology Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Preface
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets The Targets of Curcumin
Current Drug Targets Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Epigenetics Changes in the RA Synovium
Current Rheumatology Reviews TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Osteoarthritis: Is there a Window of Opportunity
Current Rheumatology Reviews Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Role of Vitamin D in the Pathophysiology and Treatment of Type 2 Diabetes
Current Diabetes Reviews Cytokines and Growth Factors in the Treatment of Osteoarthritis: What Could be the Best Disease Modifying Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database
Current Rheumatology Reviews Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry